Edition:
United States

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

10.29USD
15 Dec 2017
Change (% chg)

$0.22 (+2.18%)
Prev Close
$10.07
Open
$10.02
Day's High
$10.34
Day's Low
$9.41
Volume
47,914
Avg. Vol
13,916
52-wk High
$15.34
52-wk Low
$9.41

Latest Key Developments (Source: Significant Developments)

Aileron Therapeutics posts Q3 loss of $0.45 per share
Thursday, 9 Nov 2017 04:18pm EST 

Nov 9 (Reuters) - Aileron Therapeutics Inc :Aileron therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.45.Q3 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Cash, cash equivalents and investments as of Sept. 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016​.Qtrly ‍non-gaap net loss per share attributable to common stockholders $0.43​.  Full Article

Aileron Therapeutics reports second quarter 2017 financial results
Thursday, 10 Aug 2017 04:10pm EDT 

Aug 10 (Reuters) - Aileron Therapeutics Inc :Aileron Therapeutics reports second quarter 2017 financial results.Q2 loss per share $10.98.Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Aileron Therapeutics shares open 8.3 pct below IPO price in debut
Thursday, 29 Jun 2017 11:18am EDT 

June 29 (Reuters) - :Aileron therapeutics inc shares open at $13.75 in debut on the nasdaq versus ipo price of $15.00 per share.  Full Article

Aileron Therapeutics prices IPO at $15 per share
Wednesday, 28 Jun 2017 10:06pm EDT 

June 29 (Reuters) - Aileron Therapeutics Inc :Aileron therapeutics announces pricing of initial public offering.Aileron therapeutics-announced pricing of initial public offering of 3.7 million shares of common stock at a public offering price of $15.00 per share.  Full Article

Aileron Therapeutics sees IPO of 3.75 mln shares of common stock to be priced between $15-$17/shr
Monday, 19 Jun 2017 08:48am EDT 

June 19 (Reuters) - Aileron Therapeutics Inc :Aileron Therapeutics Inc sees IPO of 3.75 million shares of common stock to be priced between $15 and $17 per share - SEC filing.Aileron Therapeutics says will use IPO net proceeds together with existing cash about $7.0 million to fund ongoing clinical trials of ALRN-6924.Aileron Therapeutics says will use IPO net proceeds together with existing cash about $30-$35 million to fund potential expansion of ongoing clinical trials of ALRN-6924.  Full Article

Aileron Therapeutics appoints Donald Dougherty as CFO
Thursday, 15 Jun 2017 07:00am EDT 

June 15 (Reuters) - Aileron Therapeutics Inc ::Aileron Therapeutics appoints Donald Dougherty as senior vice president and chief financial officer.Aileron Therapeutics Inc - appointment of Donald Dougherty as senior vice president and chief financial officer, effective June 8th.  Full Article